(Rac) -Beraprost (sodium)

(Rac) -Beraprost ((Rac) -ML 1129) sodium is a racemic isomer of Beraprost sodium (HY-13569A) . Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis[1][2].

Product Specifications

CAS Number

[88475-69-8]

Product Name Alternative

(Rac) -TRK-100; (Rac) -ML 1129 (sodium)

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rac-beraprost-sodium-6.html

Purity

99.0

Smiles

O=C(CCCC1=CC=CC2=C1OC3CC(C(C23)/C=C/C(C(CC#CC)C)O)O)O[Na]

Molecular Formula

C24H29NaO5

Molecular Weight

420.47

Precautions

H315, H319, H335

References & Citations

[1]Li S, et al. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl) . 2019 Jun;97 (6) :777-791.|[2]Yan P, et al. Clinical efficacy and safety of beraprost sodium in the treatment of nephrotic syndrome: A meta-analysis. Medicine (Baltimore) . 2023 Oct 20;102 (42) :e34958.